[Concentrate of coagulation factor IX: viral validation of the thermoinactivation process].

The coagulation factor IX obtained at the Institute of Haematology and Transfusion in Warsaw was subjected to virological validation. Two lipide enveloped viruses were used: HSV-1 and Sindbis which may be a model for the viruses of B and C types in hepatitis. It was shown that heating of the freeze-drying preparations at 80 degrees C during 72 hrs leads to full inactivation of the added model viruses.

[Viral validation of the bio-globulin production process].

Intravenous human immunoglobulin of domestic production was subjected to validation studies. Tests were performed in the system of model viruses for pathogenic factors of the B and C types of hepatitis. For simulated immunoglobulin infections two lipid-enveloped viruses were chosen: the first DNA virus pseudorabies PR-75 (model for HBV) and the second-RNA virus Sindbis (model for HCV).

[Polish preparations for preventing and treating infections caused by Pseudomonas aeruginosa].

Three preparations, viz. sheep serum for local application ("Sanoserum"), anti-Pseudomonas sheep immunoglobulin for passive immunization ("Immunoglobulin Pseudomonas") and Pseudomonas vaccine for active immunization ("Pseudovac"), have been obtained at the Central Laboratory of Sera and Vaccines in Warsaw, Poland. The laboratory study and clinical trial of these preparations have been carried out.

Anti-Pseudomonas immunoglobulin. IV. Combined anti-Pseudomonas immunoglobulin and Pseudomonas vaccine immunotherapy of burned patients--clinical investigations.

Sheep anti-Pseudomonas immunoglobulin and Pseudomonas vaccine were used for combined immunotherapy in 55 severely burned patients. The results of clinical investigations show that active and passive immunization in the early state of thermal injury increases the anti-Pseudomonas agglutinin titer, diminish the threat of Pseudomonas sepsis and death and significantly accelerate the recovery.

Anti-Pseudomonas immunoglobulin. III. Preliminary clinical evaluation.

Preliminary clinical evaluation of sheep anti-Pseudomonas immunoglobulin was performed on 20 burn injured patients. The patients were divided into two comparable groups of ten persons. One group was treated with the immunoglobulin shortly after thermal injury (in about two days).